Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01709461
Verified June 2012 by Rabin Medical Center. Recruitment status was: Not yet recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.
subjects who are willing to contiue this treatment.
subjects who took part in the TVP 1012/501 clinical trail.
subjects who didn't take part in the TVP 1012/501 clinical trail.